104 related articles for article (PubMed ID: 1725997)
1. Introduction. Why a new calcium antagonist?
Zanchetti A
J Cardiovasc Pharmacol; 1991; 17 Suppl 4():v-vii. PubMed ID: 1725997
[No Abstract] [Full Text] [Related]
2. Effect of a new calcium antagonist on hemodynamics at rest and exercise loading in patients with essential hypertension.
Suzuki S; Hashimoto T; Kusano S; Kapuku K; Utsunomiya T; Yano K
Arzneimittelforschung; 1993 Nov; 43(11):1152-6. PubMed ID: 8292057
[TBL] [Abstract][Full Text] [Related]
3. Lacidipine and circadian variation in blood pressure: considerations for therapy.
Raftery EB
J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S20-5; discussion S25-6. PubMed ID: 1726001
[TBL] [Abstract][Full Text] [Related]
4. [Lercanidipine, a third generation calcium antagonist. Which advantages?].
Meier P; Burnier M
Rev Med Suisse; 2006 Sep; 2(78):2047-50, 2052-3. PubMed ID: 17019840
[TBL] [Abstract][Full Text] [Related]
5. [Hypertensive patients can benefit from a new generation of calcium channel blockers. Lercanidipine: effective with few side effects].
Borghi C
Rev Med Suisse; 2006 May; 2(65):1266-7. PubMed ID: 16767882
[No Abstract] [Full Text] [Related]
6. [Modern calcium channel blockade. Lowering blood pressure with added benefits].
MMW Fortschr Med; 2001 Feb; 143(6):57. PubMed ID: 11247372
[No Abstract] [Full Text] [Related]
7. [Do the newer calcium channel blockers replace the older ones?].
Jounela A
Duodecim; 1993; 109(20):1815-20. PubMed ID: 7737004
[No Abstract] [Full Text] [Related]
8. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
Hypertens Res; 2008 Dec; 31(12):2147-54. PubMed ID: 19139604
[TBL] [Abstract][Full Text] [Related]
9. Ambulatory blood pressure monitoring in elderly hypertensives treated with the new calcium antagonist, pranidipine (OPC-13340).
Tominaga M; Tsuchihashi T; Kinoshita H; Kobayashi K; Ohya Y; Abe I; Takata Y; Fujishima M
Int J Clin Pharmacol Ther; 1995 May; 33(5):277-80. PubMed ID: 7655766
[TBL] [Abstract][Full Text] [Related]
10. Calcium-channel blockers in the management of essential hypertension.
Wallis DE
Compr Ther; 1989 Nov; 15(11):14-9. PubMed ID: 2684479
[TBL] [Abstract][Full Text] [Related]
11. Effects of a new calcium channel blocker, MPC-1304, on blood pressure, serum lipoproteins and serum carbohydrate metabolism in patients with essential hypertension.
Sasaki J; Kajiyama G; Kusukawa R; Shichiri M; Sunaga T; Mashiba H; Tanaka N; Nonaka K; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jun; 33(6):366-70. PubMed ID: 7582390
[TBL] [Abstract][Full Text] [Related]
12. Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in nondiabetic patients with hypertension.
Koh KK; Quon MJ; Lee SJ; Han SH; Ahn JY; Kim JA; Chung WJ; Lee Y; Shin EK
Diabetes Care; 2007 Jun; 30(6):1605-7. PubMed ID: 17351278
[No Abstract] [Full Text] [Related]
13. [New calcium antagonist. Therapy of hypertension becomes more tolerable].
MMW Fortschr Med; 2001 Oct; 143(40):56-7. PubMed ID: 11692852
[No Abstract] [Full Text] [Related]
14. Some similarities and differences between verapamil and the dihydropyridines.
Antonios TF; MacGregor GA
J Hypertens Suppl; 1998 Jan; 16(1):S31-4. PubMed ID: 9534094
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of lacidipine, a vascular-selective calcium antagonist.
Micheli D; Ratti E; Toson G; Gaviraghi G
J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S1-8. PubMed ID: 1725998
[TBL] [Abstract][Full Text] [Related]
16. [Also for problem cases; successful first line therapy].
MMW Fortschr Med; 2005 Feb; 147(5):47. PubMed ID: 15766030
[No Abstract] [Full Text] [Related]
17. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs.
Ueda M; Matsumura S; Masui M; Matsuura E; Kawakami M; Fujitomo H; Umeda T; Kagawa H; Hirohata S; Shima K
Arzneimittelforschung; 1993 Dec; 43(12):1282-90. PubMed ID: 8141815
[TBL] [Abstract][Full Text] [Related]
18. [Comparative hypotensive effectiveness of various calcium antagonists in patients with persistent essential hypertension (randomized study)].
Akhadov ShV; Belousov IuB; Borisova EO; Volkov MG
Kardiologiia; 1992; 32(11-12):13-5. PubMed ID: 1297870
[No Abstract] [Full Text] [Related]
19. [Drug information about lercanidipine. A new dihydropyridine calcium antagonist for the treatment of arterial hypertension].
Christensen KL
Ugeskr Laeger; 2005 Jan; 167(2):153-5. PubMed ID: 15697124
[No Abstract] [Full Text] [Related]
20. Isradipine, catecholamines, and pheochromocytoma.
Januszewicz W; Wocial B; Chodakowska J; Feltynowski T; Lapiński M
Am J Hypertens; 1991 Nov; 4(11):916-7. PubMed ID: 1838694
[No Abstract] [Full Text] [Related]
[Next] [New Search]
